Clinical trial · Interventional
A Study of BMS-582664 in Patients With Advanced or Metastatic Solid Tumors
Phase I Multiple Ascending Dose Study to Determine the Safety, Pharmacokinetics and Pharmacodynamics of BMS-582664 in Japanese Patients With Advanced or Metastatic Solid Tumors
NCT00390936CI-TRIAL-00004344completedPhase 1ClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The purpose of this study is to assess the dose limiting toxicity (DLT) of BMS-582664 and the maximum tolerated dose(MTD) in subjects with advanced or metastatic solid tumors.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Solid Tumors | Solid Neoplasm | CURATED_BROADER | 0.80 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Brivanib | Drug | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- type
- NO_INTERVENTION
- label
- 1
- description
- 4 dosages
- interventionNames
- Drug: Brivanib
Primary outcomes (2)
- measure
- Dose Limiting Toxicity
- timeFrame
- at the end of the first cycle of the study
- measure
- Maximum Tolerated Dose
- timeFrame
- at the end of the first cycle of the study
Secondary outcomes (1)
- measure
- To assess any preliminary evidence of anti-tumor activity observed with BMS-582664
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 20 Years
Show eligibility criteria text
Inclusion Criteria: * Patients must have measurable disease * Documented failure to standard therapies exist, or which are determined to be inappropriate by the investigator * ECOG PS: 0-1 Exclusion Criteria: * Subjects with centrally located squamous cell carcinoma of the lung
References
Publications (0)
Data not yet available
No reference posted for this study.